Pharma Should Note Key Differences With Chinese IP Laws, Panelists Say

摘要

Philadelphia - Pharmaceutical companies accustomed to working in the United States or Europe should be aware of key differences in intellectual property laws when doing business in China, panelists said at the US-China Pharma Conference in Philadelphia on May 10. "You have to take into account all the nuances and the cultural differences," said panelist Richard B. Racine, an attorney at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Companies and practitioners should work closely from the beginning to make sure that "everything is properly covered and there are no surprises," he said.